Introduction
Thyroglobulin (Tg), a large glycoprotein stored in the follicular colloid of the thyroid gland, is produced only by the normal thyroid gland or well-differentiated thyroid cancer (DTC) cells, including papillary thyroid cancer (PTC) cells. 1, 2) Serum Tg is a very specific tumor marker for patients with DTC and shows high specificity for detecting DTC recurrence. [3] [4] [5] Although DTC patients who were considered clinically free of tumor had serum Tg levels of ＜1 ng/mL with a suppressed thyroid-stimulating hormone (TSH), 21% of these patients had serum Tg levels of ＞2 ng/mL after recombinant human TSH (rhTSH) stimulation. 6) Moreover, one-third of this patient population had metastatic DTC lesions. 6) Hence, it is important to measure the serum Tg level after appropriate serum TSH elevation, the level of which is yet to be determined, however, commonly accepted as a TSH level of more than 30 μIU/mL after thyroid hormone withdrawal (off-thyroxine) or rhTSH stimulation in order to effectively detect DTC recurrence. The American
Thyroid Association guidelines suggest that further investigation for DTC recurrence is required when the serum Tg level is ＞2 ng/mL following serum TSH elevation. 7) Further, empirical radio-iodine (RAI) treatment should be considered in patients with Tg levels of ＞5 ng/mL after rhTSH stimulation or ＞10 ng/mL after thyroid hormone withdrawal, even if the results of diagnostic RAI scan and neck ultrasonography are negative. 8, 9) However, it is unknown whether a serum TSH level of 30 μIU/mL is adequate for measuring the offthyroxine Tg level and whether a single off-thyroxine serum Tg level is sufficient for determining further RAI treatment. In this study, we evaluated the relationship between the increments of serum TSH and Tg levels in PTC patients whose off-thyroxine serum TSH and Tg levels were measured serially, and, then, evaluated the clinical utility of serial measurements of off-thyroxine serum TSH and Tg levels for predicting PTC metastasis as compared with single measurement of off-thyroxine Tg level.
Materials and Methods
Patients in the MD group than in the non-MD group (Table 1; p＜0.05 each). The Tg ratio value tended to be higher in the MD group than in the non-MD group, but the significance was marginal (p=0.05).
Results

Characteristics of patients
The relationship between TSH inc and Tg inc and Tg ratio
There were significant correlation between TSHinc Table 2 , 41% (11 out of 27 patients) of patients with MD showed Tg A ＜10 ng/mL, although the level of TSH A in those patients were more than 30 μIU/mL which is commonly accepted as a appropriate serum TSH level to evaluate off-thyroxine Tg level. Furthermore, in 11 patients with MD who showed Tg A ＜10 ng/mL, 7 patients (64%) showed Tg B ＞10 ng/mL.
We also evaluated the clinical role Tg inc /TSH inc and
Tg ratio /TSH inc in a subgroup of 43 patients with TSH A ＞ 30 μIU/mL and Tg A ＜10 ng/mL who seemed to have insufficient serum levels of TgA for empirical RAI treat- were from the non-MD group. All 9 patients in MD group were diagnosed with neck lymph node metastases at follow-up (as in Fig. 2) . The data of MD and non-MD subgroup patients are summarized in Table 3 .
Furthermore, the characteristics of 9 patients with MD in subgroup patients are shown in Fig. 3A) , and the AUC for Tg ratio /TSH inc was 0.794 (95% confidence interval 0.643-0.902; Fig. 3B ). The sensitivities of Tg inc /TSH inc (100%) and
Tg ratio /TSH inc (89%) for predicting patients with MD were higher than that of TgB (78%; Table 5 ).
Discussion
In this study, we retrospectively examined the increments of serum TSH and Tg in PTC patients by serial measurements of serum TSH and Tg levels 7 days before RAI treatment and on the day of RAI treatment. Patients with MD showed significantly higher Although empirical RAI treatment in patients with a high Tg level but a negative RAI scan is still somewhat controversial, 8, 9, [15] [16] [17] empirical RAI treatment is routinely considered in patients with a off-thyroxine serum Tg level ＞10 ng/mL. 8, 9, 15) A serum Tg level with serum TSH level of more than 30 μIU/mL is commonly accepted as off-thyroxine serum Tg level.
However, 41% of patients with MD in our study showed Tg A ＜10 ng/mL, even though the level of TSH A was more than 30 μIU/mL. Moreover, 64% of these patients showed Tg＞10 ng/mL after further increase of serum TSH level, suggesting that serum The results of subgroup analysis in our study also revealed that 2 of 9 patients with MD had off-thyroxine serum Tg level of less than 10 ng/mL. whereas FTC is relatively rare subtype, less than 2%. 20) Furthermore, a previous study showed that the median fold increase in Tg after TSH stimulation was higher in PTC than FTC, suggesting that the histological type of DTC influences the Tg increment after TSH stimulation. 11) Although a small number of patients in our medical center had FTC, we excluded patients with FTC to avoid the effect of histological type.
Our study had several limitations. First, the study was retrospectively performed and the enrolled patients with MD had clinically evident metastatic lesions.
Therefore, the use of serial measurement of offthyroxine serum TSH and Tg levels in the clinical management of patients with high off-thyroxine Tg levels but negative diagnostic image tests should be evaluated in further studies. Second, because the upper limit of our serum TSH assay is 100 μIU/mL, all serum TSH levels of more than 100 μIU/mL were reported as 100 μIU/mL, which could affect the value of Tg inc /TSH inc and Tg ratio /TSH inc . Third, the first measurement of off-thyroxine serum TSH and Tg levels was obtained over a wide range of days for different patients (5-14 days). Finally, the MD group in our study had metastatic lesions on various organs (lung, neck, and mediastinum). The site of the metastatic lesion might affect the increment in serum Tg, although a previous study showed that the loca-tion of metastatic lesions did not influence Tg responsiveness to rhTSH.
11)
In summary, PTC patients with metastatic lesions showed a high level of the serum Tg increment on serial measurements obtained after thyroid hormone withdrawal. A significant correlation was observed between the increment in serum TSH and Tg in patients with metastases. Furthermore, the increment in serum Tg corrected for the increment in serum TSH had higher sensitivity than a single off-thyroxine serum Tg level for predicting patients with metastases who had serum TSH＞30 μIU/mL and serum Tg＜10 ng/mL 7 days before RAI treatment. Serial measurement of off-thyroxine serum TSH and Tg levels can be helpful for predicting metastases in PTC patients.
